HK1075010A1 - Gaba enhancers in the treatment of diseases relating to reduced neurosteroid activity - Google Patents

Gaba enhancers in the treatment of diseases relating to reduced neurosteroid activity

Info

Publication number
HK1075010A1
HK1075010A1 HK05107388A HK05107388A HK1075010A1 HK 1075010 A1 HK1075010 A1 HK 1075010A1 HK 05107388 A HK05107388 A HK 05107388A HK 05107388 A HK05107388 A HK 05107388A HK 1075010 A1 HK1075010 A1 HK 1075010A1
Authority
HK
Hong Kong
Prior art keywords
treatment
diseases relating
gaba
enhancers
activity
Prior art date
Application number
HK05107388A
Other languages
English (en)
Inventor
Bjarke Ebert
Peter Hongaard Andersen
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8159857&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1075010(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of HK1075010A1 publication Critical patent/HK1075010A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
HK05107388A 2000-11-20 2005-08-23 Gaba enhancers in the treatment of diseases relating to reduced neurosteroid activity HK1075010A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200001743 2000-11-20
PCT/DK2001/000773 WO2002040009A1 (en) 2000-11-20 2001-11-20 Gaba enhancers in the treatment of diseases relating to reduced neurosteroid activity

Publications (1)

Publication Number Publication Date
HK1075010A1 true HK1075010A1 (en) 2005-12-02

Family

ID=8159857

Family Applications (1)

Application Number Title Priority Date Filing Date
HK05107388A HK1075010A1 (en) 2000-11-20 2005-08-23 Gaba enhancers in the treatment of diseases relating to reduced neurosteroid activity

Country Status (34)

Country Link
US (2) US20040024038A1 (xx)
EP (1) EP1337247B1 (xx)
JP (1) JP4152186B2 (xx)
KR (1) KR100865651B1 (xx)
CN (1) CN1318027C (xx)
AR (1) AR031473A1 (xx)
AT (1) ATE336242T1 (xx)
AU (2) AU2002223514B2 (xx)
BG (1) BG107909A (xx)
BR (1) BR0115668A (xx)
CA (1) CA2429220C (xx)
CY (1) CY1106209T1 (xx)
CZ (1) CZ20031383A3 (xx)
DE (1) DE60122368T2 (xx)
DK (1) DK1337247T3 (xx)
EA (1) EA007287B1 (xx)
ES (1) ES2266308T3 (xx)
HK (1) HK1075010A1 (xx)
HR (1) HRP20030404A2 (xx)
HU (1) HUP0400505A3 (xx)
IL (1) IL155587A0 (xx)
IS (1) IS2427B (xx)
ME (1) MEP6408A (xx)
MX (1) MXPA03004349A (xx)
NO (1) NO20032271L (xx)
NZ (1) NZ525520A (xx)
PL (1) PL361051A1 (xx)
PT (1) PT1337247E (xx)
SI (1) SI1337247T1 (xx)
SK (1) SK7682003A3 (xx)
UA (1) UA77403C2 (xx)
WO (1) WO2002040009A1 (xx)
YU (1) YU39003A (xx)
ZA (1) ZA200303289B (xx)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US20050031772A1 (en) * 2001-11-26 2005-02-10 Frauke Gaedcke Ginger extract preparation
PT1641456E (pt) * 2003-06-25 2010-06-01 Lundbeck & Co As H Gaboxadol para o tratamento de depressão e outros distúrbios afectivos
GB0402118D0 (en) 2004-01-30 2004-03-03 Merck Sharp & Dohme Polymorphic forms of a GABAA agonist
CN1976700A (zh) * 2004-06-29 2007-06-06 H.隆德贝克有限公司 神经性疼痛、纤维肌痛或类风湿关节炎的治疗
WO2006012563A2 (en) * 2004-07-23 2006-02-02 The Regents Of The University Of California Method for the treatment and diagnosis of certain psychiatric disorders related to the menstrual cycle
GB0417558D0 (en) * 2004-08-06 2004-09-08 Merck Sharp & Dohme Novel combination therapy
EP1848420A4 (en) 2005-01-28 2008-01-23 Merck & Co Inc POLYMORPHIC FORMS OF A GABAA AGONIST
US20070122507A1 (en) * 2005-05-26 2007-05-31 Palu Afa K Histone deacetylase and tumor necrosis factor converting enzyme inhibition
WO2008085201A2 (en) * 2006-12-29 2008-07-17 Prodea Systems, Inc. Managed file backup and restore at remote storage locations through multi-services gateway device at user premises
US20080280983A1 (en) * 2007-05-09 2008-11-13 Cenerx Biopharma Methods of treating rett syndrome
CN101585862B (zh) * 2008-05-20 2014-12-17 梅克芳股份公司 甾族化合物
CN103547240B (zh) * 2011-06-16 2016-03-30 索雷斯生命科学公司 用于人类自主神经系统的平衡和维持健康的系统和方法
RU2496496C1 (ru) * 2012-10-04 2013-10-27 Исаак Григорьевич Гитлин Фармацевтическая композиция, обладающая гамк-ергической активностью
EP3481387A4 (en) * 2016-08-11 2020-04-08 Ovid Therapeutics Inc METHOD AND COMPOSITIONS FOR TREATING EPILEPTIC DISEASES
US20180338959A1 (en) * 2017-05-24 2018-11-29 Ovid Therapeutics Inc. Treatment of depressive disorders
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
KR102049522B1 (ko) * 2018-06-05 2019-11-27 충남대학교산학협력단 Gaba를 유효성분으로 하는 살모넬라 감염질환의 예방 및 치료용 조성물
KR102049526B1 (ko) * 2018-06-05 2019-11-27 충남대학교산학협력단 Gaba를 유효성분으로 하는 항결핵 약학 조성물
WO2020061410A1 (en) 2018-09-20 2020-03-26 Ovid Therapeutics Inc. Use of gaboxadol for the treatment of tourette syndrome, tics and stuttering
EP3883566A4 (en) 2018-11-21 2022-09-07 Certego Therapeutics Inc. GABOXADOL FOR SUICIDE RISK REDUCTION AND RAPID DEPRESSION RELIEF
MX2021007224A (es) 2018-12-17 2021-09-23 Ovid Therapeutics Inc Uso de gaboxadol para el tratamiento del trastorno del sue?o vigilia que no es de 24 horas.
CA3138094A1 (en) 2019-04-17 2020-10-22 Compass Pathfinder Limited Methods for treating anxiety disorders, headache disorders, and eating disorders with psilocybin
KR20220114572A (ko) 2019-12-18 2022-08-17 오비드 테라퓨틱스 인크. 1p36 결실 증후군의 치료적 치료를 위한 가복사돌
MX2022014599A (es) 2020-05-20 2022-12-16 Certego Therapeutics Inc Gaboxadol deuterado en anillo y su uso para el tratamiento de trastornos psiquiatricos.
CN114404437A (zh) * 2022-03-15 2022-04-29 山东中医药大学 没食子酰芍药苷在制备gabaa受体抑制剂中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4362731A (en) * 1980-09-01 1982-12-07 Sandoz Ltd. Myotonolytic use of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol and derivatives thereof
US5120723A (en) * 1987-08-25 1992-06-09 University Of Southern California Method, compositions, and compounds for modulating brain excitability
EP0603312A4 (en) * 1991-09-13 1995-06-07 Cocensys Inc NEW GABA A RECEPTOR WITH STEROID BINDING POINTS.
US5206415A (en) * 1991-12-20 1993-04-27 Washington University Tricyclic steroid analogs
CZ300694A3 (en) * 1993-12-02 1996-05-15 Akzo Nobel Nv Substituted 2beta-morpholinandrostane derivatives, process of their preparation, their use for preparing pharmaceutical preparations and pharmaceutical compositions containing thereof
DE69519945T2 (de) * 1994-11-23 2001-06-07 Cocensys, Inc. Androstan- und pregnanserien für die allosterische modulation des gaba-rezeptors
US5776959A (en) * 1995-06-05 1998-07-07 Washington University Anticonvulsant and anxiolytic lactam and thiolactam derivatives
ES2235187T3 (es) * 1995-06-06 2005-07-01 Euro-Celtique S.A. Esteroides neuroactivos de las series del androstano y el pregnano.
IT1290003B1 (it) * 1997-03-03 1998-10-19 Angelini Ricerche Spa Uso di pivagabina per preparare composizioni farmaceutiche
GB9801208D0 (en) * 1998-01-21 1998-03-18 Merck Sharp & Dohme Therapeutic agents
PT1098871E (pt) * 1998-07-22 2003-11-28 Akzo Nobel Nv Derivados de ester fenilico de alfa-aminoacidos
PT1237847E (pt) * 1999-12-08 2006-08-31 Warner Lambert Co Metodo para a sintese estereosselectiva de aminoacidos ciclicos

Also Published As

Publication number Publication date
BR0115668A (pt) 2003-09-02
KR100865651B1 (ko) 2008-10-29
IS6803A (is) 2003-04-30
AU2002223514B2 (en) 2006-11-30
SI1337247T1 (sl) 2006-12-31
EP1337247A1 (en) 2003-08-27
NO20032271D0 (no) 2003-05-20
DK1337247T3 (da) 2006-12-04
US20040024038A1 (en) 2004-02-05
EA007287B1 (ru) 2006-08-25
ES2266308T3 (es) 2007-03-01
IL155587A0 (en) 2003-11-23
HUP0400505A3 (en) 2008-08-28
JP2004513921A (ja) 2004-05-13
SK7682003A3 (en) 2003-10-07
EP1337247B1 (en) 2006-08-16
IS2427B (is) 2008-10-15
KR20030065517A (ko) 2003-08-06
CN1592616A (zh) 2005-03-09
CY1106209T1 (el) 2011-06-08
US20090143435A1 (en) 2009-06-04
WO2002040009A1 (en) 2002-05-23
HRP20030404A2 (en) 2005-04-30
CA2429220C (en) 2009-09-15
ZA200303289B (en) 2005-07-27
AR031473A1 (es) 2003-09-24
YU39003A (sh) 2006-05-25
DE60122368T2 (de) 2007-08-09
ATE336242T1 (de) 2006-09-15
CA2429220A1 (en) 2002-05-23
CN1318027C (zh) 2007-05-30
EA200300594A1 (ru) 2003-10-30
PL361051A1 (en) 2004-09-20
PT1337247E (pt) 2006-11-30
BG107909A (bg) 2004-08-31
AU2351402A (en) 2002-05-27
NO20032271L (no) 2003-05-20
MEP6408A (xx) 2010-02-10
DE60122368D1 (de) 2006-09-28
UA77403C2 (en) 2006-12-15
JP4152186B2 (ja) 2008-09-17
MXPA03004349A (es) 2003-08-19
CZ20031383A3 (cs) 2003-08-13
NZ525520A (en) 2005-04-29
HUP0400505A2 (hu) 2004-07-28

Similar Documents

Publication Publication Date Title
HK1075010A1 (en) Gaba enhancers in the treatment of diseases relating to reduced neurosteroid activity
IL155092A0 (en) Compounds useful in the treatment of inflammatory diseases
GB0028926D0 (en) Improvements relating to skin prickers
AU2003239568A1 (en) Pyrrolotriazinone compounds and their use to treat diseases
IL162533A0 (en) Chalcone derivatives and their use to treat diseases
AU5114601A (en) Method for the treatment of dermal lesions caused by envenomation
GB0103973D0 (en) Improvements relating to skin prickers
EP1404343A4 (en) THERAPEUTIC COMBINATIONS FOR THE TREATMENT OF HORMONE DEFICIENCIES
ZA200707934B (en) Thereapeutic formulations for the treatment of beta-amyloid related diseases
AU7138601A (en) Methods of treating neutrophil-related diseases with topical anesthetics
GB0103977D0 (en) Improvements relating to skin prickers
IL166016A0 (en) Topical treatment of skin diseases
IL155174A0 (en) Methods and compositions for the treatment of inflammatory diseases
AU2002352566A1 (en) Use of corrinoids in the treatment of skin diseases
AU2003251407A8 (en) Topical treatment for skin irritation
GB2360453B (en) Treatment of skin conditions
AU2003226582A1 (en) Use of beta-aminoisobutyric acid for the treatment of diseases linked to the accumulation of triglycerides and cholesterol
EP1150669A4 (en) FORMULATIONS ON L-ARGININE BASE FOR DISEASE TREATMENT AND USE THEREOF
HUP0302882A3 (en) Improved specificity in treatment of diseases
AU4838301A (en) Treatment of disorders relating to the serotonergic system
GB0007217D0 (en) Materials and methods relating to the treatment of leukaemias
AU2003295504A8 (en) Development of therapeutics for the treatment of endotoxin-mediated diseases
NO20031080D0 (no) Fettsyreanaloger for behandling av profilerende hudsykdommer
AU8679801A (en) Methods and pharmaceutical compositions employing desmethylselegiline to treat neoplastic diseases or conditions
AU2003266210A8 (en) Use of mas-compounds for treating diseases associated with lipid metabolism

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20111120